RESUMO
BACKGROUND: Vulvar melanoma (VM) is rare and is often diagnosed late. Dermoscopy may aid in its recognition, differentiating VM from other more common vulvar lesions, such as melanosis and naevi. However, little is known about the dermoscopic features of thin VM. AIM: To retrospectively analyse a series of histopathologically diagnosed thin VMs and to highlight their most suggestive dermoscopic features. METHODS: A multicentre, retrospective study was conducted, including histopathologically proven thin VMs, either intraepidermal or with Breslow thickness ≤ 0.5 mm, diagnosed during the period 2016-2018. We particularly focused on their dermoscopic characteristics to highlight the most suggestive dermoscopic diagnostic clues. RESULTS: In total, 14 cases of early-stage VM were included, in women with a mean age at diagnosis of 64.86 years. The most frequently affected sites were the labia minora. Of these, 11 cases were unifocal. Dermoscopy most often revealed structureless areas, grey globules and areas, irregular black-brown dots, blue and white structures, and red areas. CONCLUSIONS: In our experience, early-stage VM often exhibits dermoscopic features that are more typical of thicker cutaneous melanomas. Dermoscopy may provide useful clues for the prompt diagnosis of thin VM.
Assuntos
Dermoscopia , Melanoma/patologia , Vulva/patologia , Neoplasias Vulvares/patologia , Idoso , Idoso de 80 Anos ou mais , Dermoscopia/métodos , Feminino , Genitália Feminina/patologia , Humanos , Melanoma/diagnóstico , Pessoa de Meia-Idade , Estudos Retrospectivos , Neoplasias Vulvares/diagnósticoAssuntos
Carcinoma in Situ/patologia , Neoplasias Vulvares/patologia , Adulto , Dermoscopia , Feminino , HumanosAssuntos
Carcinoma in Situ/diagnóstico , Carcinoma de Células Escamosas/diagnóstico , Neoplasias Vulvares/diagnóstico , Carcinoma in Situ/patologia , Carcinoma de Células Escamosas/patologia , Cor , Diagnóstico Diferencial , Feminino , Humanos , Invasividade Neoplásica , Vulva/patologia , Neoplasias Vulvares/patologiaRESUMO
OBJECTIVE: Human PapillomaVirus (HPV) vaccination has been introduced in recent years in clinical practice as the most effective primary prevention strategy for cervical cancer and HPV-induced lesions, either pre-malignant or benign. Since its introduction, HPV vaccination has been progressively demonstrated as extremely effective in preventing extra-genital and male diseases also; furthermore, non only adolescents but adult subjects have been investigated and reported as positively responding to vaccine immunostimulation. More recently, effectiveness of post-treatment vaccine administration has been preliminarily investigated with very promising results in terms of decreased recurrences. On this basis, we report an Italian-focused picture of the state of the art and take a position in favour of the extension of HPV vaccination to male adolescents, to older age groups and to already treated subjects.